Evidence map›Paper›PMID 28719060›Full record

ArticleJournal of viral hepatitis2018

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

B Jacka, B C Bray, T L Applegate, B D L Marshall, V D Lima, K Hayashi, K DeBeck, J Raghwani, P R Harrigan, M Krajden and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of viral hepatitis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

B JackaViral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0002-5910-853X
B C BrayThe Methodology Center, Pennsylvania University, University Park, PA, USA.
T L ApplegateViral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
B D L MarshallDepartment of Epidemiology, Brown University, Providence, RI, USA.
V D LimaBC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada.
K HayashiBC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada.
K DeBeckBC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada.
J RaghwaniDepartment of Zoology, University of Oxford, Oxford, UK.
P R HarriganBC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada.
M KrajdenBC Centre for Disease Control, Vancouver, BC, USA.
J S G MontanerBC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada.
J GrebelyViral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0002-1833-2017
University of British Columbia · CAUNSW Sydney · AUSimon Fraser University · CABC Centre for Disease Control · CABrown University · USPennsylvania State University · USUniversity of Oxford · GB

Funding

Pilot, Mentoring, and Professional Development CoreP50DA039838 · NIDA · PENNSYLVANIA STATE UNIVERSITY, THE · PI LI, RUNZE · 2015 to 2019
$13.9M
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDSU01DA038886 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI DEBECK, KORA, HAYASHI, KANNA · 2015 to 2024
$12.1M
Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDUDP1DA026182 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MONTANER, JULIO SERGIO GONZALEZ · 2008 to 2013
$3.9M
Highly Adaptive Epidemic Control Strategies for HIV Prevention in Drug UsersDP2DA040236 · NIDA · BROWN UNIVERSITY · PI MARSHALL, BRANDON DAVID LEWIS · 2015 to 2015
$2.4M
Modeling different strategies to reduce the public health impact of the HCV/HIV eR03DA033851 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI LIMA, VIVIANE DIAS · 2012 to 2013
$55k
CIHR HES- 115697CIHR HHP- 67262CIHR MOP-125948CIHR MSH-141971CIHR RAA- 79918NIDA NIH HHS DP1 DA026182NIDA NIH HHS DP2 DA040236NIDA NIH HHS P50 DA039838NIDA NIH HHS R03 DA033851NIDA NIH HHS U01 DA038886
6 · The paper itself

Abstract

This study estimated latent classes (ie, unobserved subgroups in a population) of people who use drugs in Vancouver, Canada, and examined how these classes relate to phylogenetic clustering of hepatitis C virus (HCV) infection. HCV antibody-positive people who use drugs from two cohorts in Vancouver, Canada (1996-2012), with a Core-E2 sequence were included. Time-stamped phylogenetic trees were inferred, and phylogenetic clustering was determined by time to most common recent ancestor. Latent classes were estimated, and the association with the phylogenetic clustering outcome was assessed using an inclusive classify/analyse approach. Among 699 HCV RNA-positive participants (26% female, 24% HIV+), recent drug use included injecting cocaine (80%), injecting heroin (70%), injecting cocaine/heroin (ie, speedball, 38%) and crack cocaine smoking (28%). Latent class analysis identified four distinct subgroups of drug use typologies: (i) cocaine injecting, (ii) opioid and cocaine injecting, (iii) crack cocaine smoking and (iv) heroin injecting and currently receiving opioid substitution therapy. After adjusting for age and HIV infection, compared to the group defined by heroin injecting and currently receiving opioid substitution therapy, the odds of phylogenetic cluster membership was greater in the cocaine injecting group (adjusted OR [aOR]: 3.06; 95% CI: 1.73, 5.42) and lower in the crack cocaine smoking group (aOR: 0.06; 95% CI: 0.01, 0.48). Combining latent class and phylogenetic clustering analyses provides novel insights into the complex dynamics of HCV transmission. Incorporating differing risk profiles associated with drug use may provide opportunities to further optimize and target HCV treatment and prevention strategies.

Indexed as

Cluster AnalysisGenetic VariationAdultCanadaCohort StudiesFemaleGenotypeHepacivirusHepatitis CHumansMaleMolecular EpidemiologyPhylogenySubstance-Related DisordersYoung Adultclusteringcocainecrack cocainedistal outcomehepatitis C virusheroinlatent class analysisphylogenetic

Identifiers

PMID28719060
PMCPMC5743579
OpenAlexW2738751588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.